Read our latest news, and find more about us and our portfolio companies.
Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).
Galecto, Inc. today announced the pricing of its initial public offering of 5,666,667 shares of common stock at a public offering price of $15.00 per share.
STORM Therapeutics today announces that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies
NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.
Mosa Meat announced the first closing of $55M as part of a larger Series B funding round
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials
From design to prototyping, validation, and frontline diagnostic testing in nine weeks
Sonde Health acquires NeuroLex Laboratories, Inc. to forms one of the world’s preeminent biobanks focused on vocal biomarkers
Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ — the world’s first enzymatic DNA printer.
Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry
Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies
Sonde One combines 6-second voice analysis, COVID-19 questionnaire, and body temperature reading in one app
Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial
Comment from Kai Beckmann, member, executive board, Merck KGaA
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals
To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline
ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD) and their families
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman
Spinout Announces Investment From M Ventures, the Strategic, Corporate Venture Capital Arm of Merck KGaA, Darmstadt, Germany, to Deliver Scalable, Energy-Efficient Quantum Computing Systems
To develop and launch a kit dedicated to sample preparation for single-cell RNAsequencing
Artios Pharma Limited today announces the appointment of Bryony Harrop as Vice President (VP) of Clinical Development
iOnctura SA announces the addition of new members to its Clinical Advisory Board (CAB)
Circuit elements that store information in their electrical resistances enable a brain-like form of computing, storing and processing information in the same place